Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 02/12/24
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024GlobeNewsWire • 12/13/23
Acasti Announces Second Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 11/13/23
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)GlobeNewsWire • 10/04/23
Acasti Announces First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 08/11/23
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual MeetingGlobeNewsWire • 08/09/23
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH PatientsPRNewsWire • 07/10/23
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023PRNewsWire • 07/05/23
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025PRNewsWire • 05/08/23
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDPRNewsWire • 04/04/23
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangePRNewsWire • 03/13/23
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/28/23